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Effects of Subthalamic Deep Brain Stimulation on Treating Motor Symptoms in Early
Parkinson's Disease.
ABSTRACT
Objective: Assess the efficacy of subthalamic nucleus deep brain stimulation (STN DBS) versus
solely optimal pharmacological use in early Parkinson's Disease to improve motor dysfunction.
Design: Systematic Literature Review. Methods: Searches were completed on PubMed utilizing
the MeSH terms: “subthalamic, deep brain stimulation, and early parkinson.” Using PubMed the
following limits and terms were used: published in the last 10 years, randomized controlled trial,
English, human, and removing duplicates. A total of three studies resulted after the search.
Results: All three studies showed statistically significant results in reduction in disease
progressive motor symptoms. Additionally, at the end of each study a lower dosage of levodopa
was needed to control symptoms. Conclusion: STN DBS shows promising improvements in PD
motor symptoms; however, the choice to undergo this treatment must be an individual
conversation for each patient and their provider with a risk versus benefit analysis on a case-bycase basis. Further research is needed with great sample sizes and to assess long-term effects of
STN DBS on patients with PD as the therapy is implemented years earlier than currently
approved.
INTRODUCTION
Parkinson’s disease (PD) is a disabling, incurable neurodegenerative disorder that
impacts the dopaminergic neurons in the substantia nigra.1 The main motor symptoms
characteristic of PD include bradykinesia, tremor, and rigidity. Additional motor symptoms
include cramping, drooling, dyskinesias, festination, masked facial expressions, micrographia,
and shuffling gait. While there is constant research being conducted on this disease, the
pathophysiology of PD is still not completely understood. PD is characterized by the death of
dopaminergic neurons in the substantia nigra pars compacta. The buildup of alpha-synuclein
proteins that make up Lewy bodies are thought to be the cause of the dopaminergic neuron
death.2 The substantia nigra pars contracta produces and uses the neurotransmitter dopamine to
send signals to the basal ganglia, which allows for controlled, voluntary movements. With the
death of the neurons that produce dopamine, the function of the basal ganglia is hindered, thus
causing the many motor symptoms seen in PD.2
Treatment for PD is a challenging feat. As of now, there are no treatments that reverse or
cure the disease process of PD. The purpose of treatment is to manage symptoms in order to
improve quality of life. Management requires polypharmacy as the disease progresses and more
symptoms appear. Additionally, tolerance to medications, like levodopa, require higher doses or
different combinations of medications to produce a similar effect.1 Current first-line
pharmacological treatments like levodopa tend to help motor symptoms, but also cause unwanted
side effects, which can be significant and debilitating.3,4
Deep brain stimulation (DBS) is a newer breakthrough that offers a different approach
than pharmacotherapy in the treatment of PD; however, it is not disease modifying long term.
DBS is commonly called the “pacemaker of the brain”. Magnetic resonance imaging and cell
electrical activity is used to guide electrode placement into particular areas of the brain
responsible for the abnormal motor symptom activity. Subsequently, an implantable pulse
generator (IPG) is inserted either under the collarbone or in the abdomen, which provides an
electrical impulse to those motor areas in the brain. Currently, the brain is mainly targeted in two
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areas with DBS: the subthalamic nucleus (STN) and the globus pallidus interna (GPi), both of
which have FDA approval for PD. The electrical impulse from DBS interrupts the nerve
impulses at the damaged areas of the brain that cause PD symptoms, such as tremor. Tremor was
the first symptom to show improvement with DBS in 1997. In 2002, DBS was recognized for
treatment in advanced PD. DBS was permitted for the initial stages of PD in 2016, but is still
heavily controversial and not well studied.5 Given the favorable effect DBS has on motor
symptoms of PD, this literature review investigates whether DBS in the STN is effective in early
stage PD to decrease these motor symptoms.5
Clinical question: Do patients with early PD who receive STN DBS versus only optimal drug
therapy have a slower progression of motor dysfunction?
METHODS
An initial search of PubMed was conducted in September 2020 using the search terms
“Subthalamic brain stimulation in early Parkinson’s Disease.” Three hundred and sixty two
articles were found with the absence of any duplicates. These articles were screened for
eligibility. One hundred and sixty of these articles were excluded as the studies were not
conducted on human subjects. Another 183 studies were excluded as they were not randomized
control trials. This left 19 full-text articles for further assessment. Articles were excluded if they
did not answer the clinical question, did not include motor symptom related results, or were pilot
studies to one of the three articles chosen (Figure 1). Three studies qualified for this research.
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Figure 1. PRISMA Flow Diagram
RESULTS
Study #1
Effects of Deep Brain Stimulation on Rest Tremor Progression in Early Stage Parkinson Disease
(2018)
Study Objective: To assess the progression of motor symptoms in PD patients with early DBS
therapy. 6
Study Design:
This pilot study was a prospective, randomized, controlled, single-blind study for PD
patients who are 50-75 years old. It was sponsored by and researched at Vanderbilt University.
Thirty participants were registered in the research study, but only 28 participants lasted the
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whole trial. Two participants left the study early: one dropped out and the other did not meet
inclusion criteria for the history of PD medications. Both participants were in opposite groups.
All patients had a Hoehn & Yahr score of II while “off” medication time and a history of taking
PD medications for six months to four years. The Hoen and Yahr (HY) Scale is used to define
early and advanced PD in research. Stage 1 includes unilateral involvement only with limited or
no functional disability. Stage 2 consists of bilateral or midline involvement without impairment
of balance. Stage 3 is comprised of bilateral disease, mild to moderate disability with impaired
postural reflexes, and physical independence. Stage 4 includes severely disabling disease and
still able to walk or stand unassisted. Stage 5 is defined as confinement to bed or wheelchair
unless aided. Classically, HY Stages 1 and 2 are defined as early, Stage 3 as moderate, and
Stages 4 and 5 as late disease.7 Other participant demographics were noted to be similar amongst
the group. The participants could not have a history of dyskinesia or motor symptoms to be
enrolled in the study.6
On day one of the trial each patient was videoed while “on” medication and outcomes
were measured via the UPDRS-III (Unified Parkinson’s Disease Rating Scale) scale for a
baseline evaluation. Eight days later, after a washout period, the patients were videoed while
“off” medication. At the conclusion of the baseline evaluations, participants were randomized
into groups for either ODT (optimal drug therapy) or bilateral STN DBS & ODT. Every followup visit consisted of a video recording on day one “on” therapy and on day eight “off” therapy
after a washout period. All follow-ups were conducted in the center every six months throughout
the two years of research. At baseline and at the end of the study each participant was evaluated
for how many body parts were affected by a resting tremor. New development of a resting
tremor was distinguished by limb.6
The STN DBS & ODT group was not actively treated until approximately 1.5 months
after baseline testing because of preparing for pre-op and post-op recovery. After surgery, each
patient receiving STN DBS were titrated to the efficacious dose, which took about four weeks. In
this trial the frequency and pulse width was set at 60 μs and 130 Hz using monopolar stimulation
(model 3389 leads; Medtronic, Minneapolis, MN). All patients were assigned a neurologist that
individually managed their medications. Both groups got levodopa as their standardized
medication. The doses of levodopa given were individualized.6
After the conclusion of the trial a private, blinded neurologist, who was certified in
scoring UPDRS, watched all the unlabeled videotapes and graded each patient. The neurologist
reported the UPDRS-III score which included all of the motor tests, but not rigidity because it
cannot be rated through video.6
After the trial a patient satisfaction survey was given to confront any experiences and
assess level of satisfaction. Twenty-seven participants finished the questionnaire, 14 from the
ODT group and 13 from the STN DBS & ODT group. The STN DBS & ODT group got
supplementary questions to assess their impression of DBS .6
The statistical data was analyzed by using IBM SPSS Statistics 23.0. Using Bonferroni
comparisons from a Wilcoxon rank-sum test, p was found to be <0.0038 and therefore
considered to be statistically significant. Numerous linear regression models were generated with
approximating variance and equations to assess the trend over two years for both groups.
Separate data analyses were made when patients were “on” and “off” therapy. To discover the pvalue for each group, the study used two degrees of freedom for the Chi squared test of the null
hypothesis. The study calculated the hazard ratio between both groups by using the Cox
proportional hazard model and binary terms for the treatment group. This hazard ratio assessed
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the time until the UPDRS-III score for “off” rest tremor worsened by two points on the scale. A
p-value for the between-group difference was then found via a log-rank test. At baseline and at
the end of the study each participant was evaluated for how many body parts were affected by a
resting tremor. New development of a resting tremor was distinguished by limb and statistically
analyzed by using a 2-sample t-test with variances that are equivalent. The Fisher exact test was
applied to find the difference between the development of resting tremor versus no development
of a resting tremor. In this study p <0.05 is considered to be statistically significant.6
Study Results:
At baseline the STN DBS & ODT group had a lower daily dose of levodopa and worse
“on” therapy scores for the UPDRS but neither of these things made a statistically significant
difference. The “off” therapy versus the “on” therapy scores declined for both groups. The only
“off” therapy score that reached statistical significance on the UPDRS-III score (p=0.002)
between groups was the rest tremor “off” scores by 3.1 points better in the DBS & ODT group.
The worsening resting tremor was 2.6 times greater in the ODT group versus the STN DBS &
ODT group. 6
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Figure 2. Motor outcomes of “off” therapy.6
Overall, the most statistical significance difference between the ODT and the DBS &
ODT group was the resting tremor section of the UPDRS-III analysis. In Figure 2 above, there
also shows an increase in the ODT group after 24 months in these UPDRS-III categories: action
and postural tremor, finger taps, hand movements, and rapid alternating movements. The DBS &
ODT group had an increase in score in the UPDRS-III categories: leg agility, rising from a chair,
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posture, gait, speech, and bradykinesia or hypokinesia. Both groups had approximately the same
scores in facial expression and postural instability.6
This study also assessed the mean number of limbs affected by the resting tremor for
each patient. At baseline there were 1.4± 0.8 in the ODT group and 1.6± 1.3 in the DBS & ODT
group. At the end of the two year study the ODT group had 2.8± 1.3 and the DBS & ODT group
had 1.5± 1.3. Overall, the change favored the DBS & ODT group. A total of 86% of patients in
the ODT group experienced a new resting tremor in a new limb while the DBS & ODT group
only increased by 46%. Four patients in the DBS & ODT group had a resting tremor at baseline
that went away by the end of the trial. In one patient in the DBS & ODT group, all tremors
completely vanished.6
The “on” therapy tremor was also analyzed in both groups. The DBS & ODT group was
worse than the ODT group by 1.3 points at baseline. This was not found to be statistically
significant (p= 0.18) because of the small sample size represented. The DBS & ODT group did
improve by 1.5 points over the 24 month trial for the resting tremor while “on” therapy. Whereas
the ODT group worsened by 0.9 points giving the DBS & ODT group the favorable outcome.6
When comparing both groups, the DBS & ODT group took less levodopa. The amount of
stimulation in the DBS & ODT group did have to be increased throughout the two year period
from 1.6 +/- 2V to 1.9 +/- 3 V.6
Study Critique:
A limitation of this study is that the research only spanned a course of two years, which
does not allow for observation of long-term effects of DBS that may appear for patients
receiving it at earlier stages of PD. Another limitation of the study is that UPDRS-III is supposed
to include rigidity but, because the patients were videotaped, the rigidity could not properly be
assessed. Additionally, the UPDRS-III scoring is a subjective measure without a studied
biomarker, so grader error could be present. The participants in the study were also potentially at
risk for bias because it was an open-label pilot study.
Strengths of the study include that the neurologist looking at the videos was blinded to
which treatment each patient was receiving. The study was also randomized, which increases
confidence in the results. Even though the results are favorable and statistically significant in this
pilot study, the cohort size will need to be larger before approval of DBS in early PD can be
FDA approved.6
Study #2
Neurostimulation for Parkinson's Disease with Early Motor Complications (2013)
Study Objective: To assess whether subthalamic deep brain stimulation would benefit patients
with earlier staged PD8
Study Design:
This was a two year randomized, parallel-group study that took place in Germany and
France that aimed to compare DBS with medical therapy versus medical therapy alone. The
University of Marburg in Marburg, Germany was selected as the coordinating center that
conducted the randomization process that included randomly permuted block lengths for each
center. The Declaration of Helsinki, Good Clinical Practice guidelines, and the International
Organization for Standardization 14:155 of 2003 were used as standards that the study complied
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to and an ethics committee at each center approved the study. All participants signed a written
informed consent document prior to the randomization process. Once the study began, a separate
committee for data and safety monitored continuously throughout the study. Monitors were used
to verify the data at each respective site- German centers at Koordinierungszentrum für Klinische
Studien and French centers at Department of Clinical Research, Assistance Publique- Hôpitaux
de Paris. The study was designed by the protocol committee and written by the steering
committee.8
A total of 251 participants out of 392 potential candidates were chosen to be randomly
assigned to a study arm of either stimulation plus pharmacotherapy or only pharmacotherapy
between July 2006 and November 2009. There were nine German and eight French university
centers. The participants needed a PD diagnosis with early motor complications in which the
mean age was 52 years, and the mean length of the disease was 7.5 years.8 The inclusion and
exclusion requirements for the selection of these participants can be seen in Table 1. A total of
124 participants were randomized to the deep brain stimulation study arm with 120 finishing the
study. A total of 127 participants were assigned to the pharmacotherapy only study arm with 123
finishing the study. The authors noted that after randomization, the baseline demographics and
information were similar amongst the two study arms with an average duration of disease being
7.5 years and pharmacotherapy adverse events started 1.7 years prior to enrolling in this study.8
Table 1. Inclusion and exclusion criteria for selection of participants8
Inclusion:
18-60 years old
Duration of disease 4+ years
Hoehn and Yahr scale below stage 3
Unified Parkinson’s Disease Rating Scale- part III showing 50%+ improvement of motor
symptoms with use of dopaminergic medication
Fluctuations or dyskinesias for ≤3 years
Unified Parkinson’s Disease Rating Scale- part II showing a score of >6 for activities of daily
living in the worst condition despite medical treatment
Social and Occupational Functioning Assessment Scale score of 51-81% indicating mild-to
moderate impairment of social and occupational functioning
Exclusion:
Mattis Dementia Rating Scale score of ≤130
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Beck Depression Inventory II score of >25
Acute psychosis
Any other medical or psychological problem that would interfere with the conduction of the
study protocol
Duration of disease <4 years

Within 6 weeks of randomization, the participants that were chosen for the stimulation
with pharmacotherapy arm had a stereotactic surgery that included placement of electrodes
(model 3389, Medtronic) in the STN and placement of a pulse generator (Kinetra or Soletra,
Medtronic). Protocols for surgical standards were followed to assure appropriate anesthesia,
imaging pre- and post-implantation, and microelectrode recording. DBS was provided to these
participants.8
The participants underwent assessments at baseline, 5, 12, and 24 months with a
levodopa challenge addition at baseline and 24 months. A video was taken prior to surgery and
after surgery at baseline and 24 months so that blinded assessments could have a comparison.
Each motor condition was recorded, and two blinded experts assessed the participants' UPDRSIII score from the videos with the exception of rigidity, which was assessed in person. European
Federation of Neurological Societies guidelines were used to guide medication and stimulation
adjustments to standardize the sequence of changes to therapy, which a separate expert panel
evaluated for compliance to the guidelines.8
Two suicides occurred during the study, prompting an additional procedure in the
protocol that assessed a baseline risk of suicidality and a phone interview every two months.
Psychiatric help was available when needed.8
The primary outcome measured included the Parkinson’s Disease Questionnaire (PDQ39) mean change in quality of life at baseline and two years between the two study arms. Using a
serial gatekeeper procedure, if the results were significant, the study assessed other outcomes
including motor symptoms via UPDRS-II activities of daily living, UPDRS-III severity of motor
signs, UPDRS-IV severity of treatment complications, and patient reported “good” mobility and
no dyskinesias that interfered with activities. Other minor secondary outcomes were assessed but
were not relevant to the purposes of this literature review. Any adverse events were recorded
throughout the study.8
Statistical analysis included an assumption of normally distributed data and therefore a
power of 80% was chosen for a two-sided Mann-Whitney test. The number of necessary
participants were calculated to be 246 using a standardized effect size of 0.4 with alpha=5% and
an estimated loss to follow-up of 15%. The authors noted that intention-to-treat analysis was
utilized first and that per-protocol analysis was also conducted separately. Instead of the MannWhitney test, a linear mixed-model analysis was used to allow for adjustments and
accountability of random effects. Loss to follow-up that resulted in lack of data points were
managed using direct likelihood analysis. The outcomes were evaluated using Hochberg’s
multiple-comparison method using a 5% significance level.8
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A total of 25 participants deviated from the study protocol by completing the PDQ-39
after the completion date, having an absence of motor fluctuations or dyskinesias, lacking the
entirety of the treatment, or dying during the study. This left 116 participants in the stimulation
study arm and 110 in the pharmacotherapy study arm for result analysis.8
Study Results:
PDQ-39 score measured as the primary outcome showed an enhancement of 26% in the
stimulation study arm, and a decline of 1% in the pharmacotherapy study arm between the
baseline assessment and 24 months. The between-group difference was an 8.0 point change
(p=0.002) on the score.8
Pharmacotherapy was withheld for at least 12 hours for the off-medication circumstances
in the stimulation study arm. A 53% improvement in the UPDRS-III scores were seen in the
stimulation study arm with the between-group difference at the conclusion of the study 16.4
points better in this group (p<0.001). There was noted to be no change in the pharmacotherapy
group (p<0.001). A lesser, but still statistically significant improvement in UPDRS-III scores
were observed between the stimulation arm when on-medication and on-stimulation. Levodopa
adverse events such as motor fluctuations and dyskinesias were evaluated using UPDRS-IV
scores and showed 61% amelioration in those with stimulation and a 4.1 point change was noted
between groups (p<0.001).8
UPDRS-II activities of daily living scores at the worst point in the prior week changed by
6.2 points showing stimulation was superior to medication only (p<0.001) without differences
between groups for the best point in the week. The patient reported mobility and lack of
dyskinesia was 20% better in the stimulation group and a between-group improvement of 1.9
hours (p=0.01). Poor mobility was decreased by 1.8 hours (p=0.006) for the stimulation group.
There was no significance noted in time with debilitating dyskinesia between groups.8
The levodopa medication doses decreased by 39% in the stimulation group and increased
by 21% in the pharmacotherapy participants for a total between-group difference of 609 mg
(p<0.001). Other endpoints were measured by this study; however, are not the focus of this
literature review.8
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Table 2. Study outcomes8

Adverse events were reported in both groups to be similar- 68 in the stimulation group
and 56 in the pharmacotherapy group had a minimum of one adverse event. Three suicide events
occurred, two being in the stimulation group and the other in the pharmacotherapy group. No
other deaths occurred. Side effects of suicidal ideation and suicide attempts were relatively the
same between study arms. The stimulation group did show more depression symptoms. Motor
control, impulse control, and psychotic events had a higher frequency in the pharmacotherapy
group. Only one of 26 complications related to the brain stimulation surgery caused permanent
damage, which resulted in a scar.8
Overall, 96.8% of the stimulation study arm participants and 94.5% of the
pharmacotherapy study arm participants complied with medical therapy guidelines. The mean
parameters after 24 months were 2.8±0.7V stimulation strength, 142±27 Hz for frequency, and
66±33 µs for pulse duration.8

Legaluppi, Reale 12
Study Critique:
A limitation of this study is that it only spanned the course of 24 months, which does not
allow for observation of long-term effects of DBS that may appear for those receiving it at earlier
stages of PD. Assessment of the overall safety of this therapy type cannot be determined from
this study because of its short course.
The study implemented strong and rigorous protocols with exceptional oversight and
medical care for any adverse events that occurred. The sample size was larger and appropriately
maintained. The randomization and blinded format of the study are also strengths of this study.
The intention-to-treat and per-protocol results were very similar indicating confidence in the
validity of the results.
Study #3
Acute Effects of Subthalamic Deep Brain Stimulation on Motor Outcomes in Parkinson's
Disease; 13 Year Follow Up (2019)
Study Objective: To assess the efficacy of STN DBS on motor symptoms of Parkinson’s over 10
years.9
Study Design:
This was a prospective cohort study registered in the Clinical Trial Registry with protocol
approval from the Ruijin Hospital Ethics Committee of Shanghai Jiao Tong University School of
Medicine in Shanghai, China. Nine men and two women were chosen to be study participants for
a total of 11 patients. The study participants had a diagnosis of early-onset PD and were recruited
from patients of the Departments of Neurology and Functional Neurosurgery at Ruijin Hospital,
Shanghai Jiao Tong University School of Medicine in Shanghai, China. Inclusion criteria were
defined as the following: idiopathic PD defined by the United Kingdom Parkinson’s Disease
Society Brain Bank Clinical Diagnostic Criteria, utility of bilateral STN-DBS implant for greater
than 10 years, PD diagnosis prior to the age of 50, and length of disease time seven years or less
when surgery occurred. Exclusion criteria included unstable vital signs or other medical and/or
psychiatric comorbidities during the conduction of the study. All patients signed a written
informed consent prior to participating. Those that were selected were between the ages of 43
and 68 years old with a mean onset of PD being 38.9±7.5 years and the mean age when surgery
was completed being 43.8±8.7 years. At the onset of the study, the continuous STN-DBS
treatment the participants had already received averaged 13.4±1.3 years.9
Neurosurgery was conducted by targeting specific locations determined using 1.5T
magnetic resonance imaging (MRI). Model 3387-40, 7428 electrodes manufactured by
Medtronics in Minneapolis, MN were embedded into the subthalamic nucleus while the patient
was under local anesthesia. During the procedure, macroelectrode stimulation was utilized to
assure the appropriate position of the implanted electrodes. The programmable pulse generator
(IPG) (bilateral Itrel IIⓇ, unilateral Kinetra) manufactured by Medtronic, and the deep brain
stimulation leads and extension wires (7482) manufactured by Medtronic were placed under the
clavicle using general anesthesia. The IPG was configured the next day and the electrical
parameters were adjusted via the DBS programmer (7532, 8840 neurological programmer)
manufactured by Medtronic and included parameters such as voltage, pulse width, and
frequency. Imaging was used after surgery to assure DBS leads were in the appropriate location.
A non-rechargeable Medtronic pulse generator (model 7428 Kinetra, or 7426 Soletra™) was
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used to distribute the stimulation. Batteries necessitated replacement 3.9±1.3 times as the
average lifespan of the battery was 4.1±1.3 years. During the final battery replacement, a
Medtronic Activa™ pulse generator (model 37602 or 37612) was provided.9
Primary outcomes were severity of motor symptoms (tremor, rigidity, and
bradykinesia) as defined by UPDRS-III, gait and freezing of gait as defined by the Timed Up and
Go (TUG) test, and the disability extent and progression as defined by the Hoehn-Yahr stage.9
The stimulation details were noted at every visit in addition to at the time of any adverse
events. A formula was used to calculate the total electrical energy delivered in one second
(TEED1s) at the conclusion visit. Assessments were conducted at various times. The offmedication assessment was conducted after dopaminergic drugs were discontinued the night
prior. The on-medication assessment was obtained 45 minutes after the participant had taken
their antiparkinsonian medications with the brain stimulator on. One final assessment was taken
with the brain stimulator turned off an hour later. During visits, motor assessments were videoed
so that an examiner who was blinded to patient information and STN-DBS parameters could
score the patient’s symptoms.9
Statistical analysis was performed between stimulation on and off assessments and at
different visits using non-parametric Wilcoxon signed-ranks tests using Statistical Package for
Social Sciences for Windows. Statistically significant data were defined as two-sided p<0.05 and
adjustments for multiple testing were made using the False Discovery Rate (FDR) correction.9
Study Results:
The study showed a statistically significant improvement in the total UPDRS-III score
outcome. Specifically, there was a 54% reduction in motor symptoms in the off-medication/onstimulation versus the on-medication/off-stimulation and a 48% reduction in motor symptoms in
the on-medication/on-stimulation versus on-medication/off-stimulation. Tremor was controlled
significantly showing a 72% reduction off-medication and a 69% reduction on-medication.
Bradykinesia was reduced 45% off-medication and 40% on-medication. The summation of total
axial symptoms were reduced 51% off-medication and 44% on medication. However, dissecting
axial symptoms further gait was more responsive to the stimulation and showed a 56% reduction
off-medication and 50% reduction on-medication, while posture was only reduced 38% onmedication and 27% off-medication. The TUG scores indicate an improvement of functional
mobility with a 70% reduction of scores off-medication and a 47% reduction in scores onmedication. A 54% reduction in time percentage spent in FOG was seen off-medication and a
58% reduction was seen on-medication.9
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Table 3. Motor symptom severity of patients (N=11) before and after STN-DBS.9

After the conclusion of the final assessment, the study noted that dopaminergic
medication dosages were reduced by 53%. At baseline, the levodopa daily dose was 750±224mg,
while 13 years post-surgery the daily dose was 356±397mg. The study did mention that two
participants discontinued dopaminergic medication because of hallucinations as a side effect of
the medication and had adequate motor control. Another two participants needed less than
100mg/day of levodopa to decrease the amount of dyskinesia experienced as a side effect of the
medication.9
Pertinent stimulation parameters mentioned that monopolar stimulation with single or
double unipolar configuration was used in 90% of the cohort. The voltage needed increased over
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the course of the study; however, the frequency of stimulation was decreased. The pulse width
stayed consistent during stimulation after the first visit. The reported total electrical energy
delivered was noted to be 343.6±118.8µW.9
Table 4. Stimulation parameters at follow up visits after surgery9

During the first three months of the study, four participants experienced dyskinesia
related to the stimulation, which was managed by decreasing the amount of stimulation or
medication. During the first year, three patients gained approximately 8 kg. There were no
hardware or surgical setbacks noted throughout the study.9
The study concluded that there is statistically significant improvement in motor and axial
symptoms of early-onset PD that can be sustained. The surgery was without complications and
all stimulation side effects were managed adequately by decreasing medication doses or
adjusting stimulation parameters. The authors noted that programming should be conducted by
experts in order for patients to receive maximum benefit from this therapy.9
Study Critique:
One major limitation of this study is that the sample size is extremely small and limited
with only 11 participants. In addition, it is not a randomized control study and there were not
controls noted; however, controls would be difficult to implement in this type of study as all PD
patients manifest differently. The on and off medication circumstances studied in conjunction
with stimulation were not in a randomized order causing a lack of a wash-out period that could
have caused an alteration in results. The authors admit to the inability to receive baseline UPDRS
scores prior to the stimulation treatment. This makes comparing results pre- and post-surgery
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difficult when assessing motor symptoms, and should be considered in future long-term research
for more accurate analysis. Additionally, the study notes that dyskinesias occurred in a subset of
the participants from either the stimulation or the medication, but did not truly indicate which
was the cause of the adverse event. This is important in determining the effectiveness and utility
of stimulation.9
The study assessed various motor symptoms using three different well studied assessment
tools such as the UPDRS-III and Hoehn-Yahr stage. This offers useful credibility and ease of
understanding results to others experienced with understanding PD management. The longevity
of the study is also an asset. The study was conducted over a minimum of 10 years, providing
useful long-term data regarding this treatment option, which is not well studied in the population
of early-onset PD. The study results were noted to be consistent with previous long-term studies
managing axial symptoms; however, there are still conflicting reports noted in other studies. It is
evident that close expert management of stimulation parameters and evaluation of symptoms is
necessary to effectively incorporate this treatment option.9
DISCUSSION
Parkinson’s disease is a progressive disease without modifying or curative therapy
options. While there are many medication options to treat the symptoms of PD, these therapies
do not come without consequences and do not slow the progression of the disease. In addition,
over time the dosages must be increased to maintain the therapeutic effects that are desired. This
leads to complicated medication regimens, more side effects, and higher cost to the patients.
STN DBS offers a solution to these problems, but thus far has only been implemented
successfully in refractory cases of PD. The studies selected for this systematic review aim to
determine if implementation of this treatment modality would help motor symptoms specifically
in earlier stage PD. The pilot studies chosen, indicate promising results in the use of STN DBS in
early onset PD on motor symptoms in addition to reducing the dose of the levodopa needed in
order to control symptoms.
An overview of the three studies can be viewed in Table 5. Limitations of Hacker et al.
and Zhou et al. include extremely small sample sizes.6,9 Additionally, the Zhou et al. study did
not complete a randomized control trial, thus decreasing the strength of the results. However, the
participants were followed for 13 years, which is significantly longer than the other two studies
and thus provides a better understanding of the long-term effects of this treatment option.6,8,9
Because the goal was to evaluate the use of this therapy in earlier onset PD, it is important to
consider the long-term effects of DBS in this patient population as they will be utilizing this
modality for a much longer period of time than someone with advanced PD at the end of their
life span. No major or serious side effects were mentioned in this long-term study. Contrary to
these findings, Schuepbach et al. had a much better sample size, but reported significant
psychological adverse events, including successful suicide attempts within the two year period
the participants were followed. The authors were unable to identify and attribute the cause of
these events to the STN DBS, but this is a major consideration in considering this treatment for
those with early PD. If significant psychological adverse events occur because of STN DBS, this
may not be a treatment protocol that is worth the risk despite the positive motor benefits
reported.8
Hacker et al. focused significantly on the resting tremor. The development of new
tremors in previously unaffected limbs were noted to be significantly lower with the STN DBS, a
character not addressed in the other studies. In addition, the existing tremors were decreased to a
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statistically significant amount as well as the participants reporting that this feature of their
treatment was the most favored benefit.6 Schuepbach et al. showed strength in their sample size
and found that UPDRS-III scores decreased to a statistically significant degree (p<0.001).
Notably, the dyskinesia symptoms often seen with levodopa treatment were reduced significantly
in those receiving STN DBS, which was not discussed in other studies.8 Zhou et al. indicated
statistically significant (p<0.05) improvement in those with STN DBS in comparison to only
medication in all motor symptoms assessed except posture. UPDRS-III scores decreased,
indicating improvement of motor symptoms such as tremor, rigidity, and bradykinesia, which are
all cardinal motor symptoms in PD. Gait was shown to improve as well as the TUG test. Given
that this was the longest of the studies, the improvements of motor function appear to be
maintained long-term with the use of the STN DBS from an earlier stage of the disease.9
Each study focused on slightly different aspects of the disease manifestations; however,
collectively, all three studies showed statistically significant reductions in the tremors the
participants experienced, a hallmark symptom of PD.6,8,9 Further studies involving larger sample
sizes and longer duration trials should be done to determine the efficacy and safety of STN DBS
in earlier stages of PD. The research from these trials indicates the possibility of this treatment in
the future.
Table 5. Overview of Studies6,8,9
Study
Patients
Age
Place of Study
Population

Hacker et al.
28
50-75
Vanderbilt University
- Hoehn & Yahr score of 2
while “off” medication
time
- History of taking PD
medications for six months
to four years

Schuepbach et al.
251
18-60
Marburg, Germany
- Duration of disease 4+ years
- Hoehn and Yahr scale below
stage 3
- Unified Parkinson’s Disease
Rating Scale- part III showing
50%+ improvement of motor
symptoms with use of
dopaminergic medication
Fluctuations or dyskinesias for
≤3 years
- UPDRS-II showing a score of
>6 for activities of daily living
in the worst condition despite
medical treatment
- Social and Occupational
Functioning Assessment Scale
score of 51-81% indicating
mild-to moderate impairment of
social and occupational
functioning.

Zhou et al.
11
43-68
Shanghai, China
- Idiopathic PD defined by the
United Kingdom Parkinson’s
Disease Society Brain Bank
Clinical Diagnostic Criteria
- Utility of bilateral STN DBS
implant for greater than 10
years
- PD diagnosis prior to the age of
50
- Length of disease time seven
years or less when surgery
occurred

Study type
Measurement
scale
STN DBS
protocol

RCT
Hoehn and Yahr
UPDRS-III
- Frequency and pulse width
was set at 60 μs and 130
Hz using monopolar
stimulation

RCT
Hoehn and Yahr
UPDRS-III
- The mean parameters after 24
months were 2.8±0.7V
stimulation strength, 142±27

Prospective Cohort
Hoehn and Yahr
UPDRS-III
- Pertinent stimulation
parameters mentioned that
monopolar stimulation with
single or double unipolar
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-

Length of
Study

The amount of stimulation
in the DBS & ODT group
did have to be increased
throughout the 2 year
period from 1.6 +/- 2V to
1.9 +/- 3 V.6

2 years

Hz for frequency, and 66±33 µs
for pulse duration.8

-

-

2 years

configuration was used in 90%
of the cohort
The voltage needed increased
over the course of the study;
however, the frequency of
stimulation was decreased.
The pulse width stayed
consistent during stimulation
after the first visit. The reported
total electrical energy delivered
was noted to be
343.6±118.8µW.9

13 years

CONCLUSION
STN DBS is shown to improve motor symptoms in early PD such as an overall
improvement in the patient’s UPDRS-III scores and the ability to reduce the amount of levodopa
taken. Even though most of the results were statistically significant, due to the small cohorts in
two of the three studies and span of two of the three studies being only two years, some of the
concerns stem from the long-term impact of STN DBS. The variability among the STN DBS
protocol parameters is also a concern among these studies. Additionally, there is a limitation on
experts in DBS protocols given the specificity of the protocols and continuous monitoring and
adjustments made throughout therapy that will restrict the implementation of this treatment as
standard practice. Furthermore, insurance coverage and cost of this procedure in comparison to
medications would be a concern for PD patients. While STN DBS shows promising
improvements in PD motor symptoms, the choice to undergo this treatment must be an
individual conversation for each patient and their provider with a risk versus benefit analysis on
a case-by-case basis.
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